Abstract: The incidence of perioperative infection in liver transplant recipients is high, and strengthening the management of perioperative anti‑infection in liver transplant recipients is one of the key factors to ensure surgical success, reduce mortality, and improve recipient prognosis. Amphotericin B is a broad‑spectrum and potent polyene antifungal drug used in clinical treatment of invasive fungal diseases. There are mainly amphotericin B deoxycholate, amphotericin B liposome, amphotericin B gelatinous dispersion, and amphotericin B lipid complex available for clinical use, with the latter three being amphotericin B lipid formulations. At present, there is a lack of unified standards for the rational use of different formulations of amphotericin B during the perioperative period in liver transplant recipients. Therefore, the Perioperative Management Group of Chinese Society of Organ Transplantation organized relevant experts to follow the principles of evidence-based medicine, combined with relevant literature, expert experience, and research results from various transplant centers, to develop the Guideline on the clinical rational application of different formulations of amphotericin B for adult liver transplant recipients (2025 edition). This guideline aims to provide recommendations for the rational clinical use of amphotericin B in adult liver transplant recipients, clarify the dosage form and dose selection of different formulations of amphotericin B for the targeted treatment of invasive fungal diseases in liver transplant recipients, provide guidance for clinical decision‑making and rational use of such drugs, and improve postoperative survival rates of liver transplant recipients.